APA (7th ed.) Citation

Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., . . . Hewitt, S. (2018). Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 52, 16. https://doi.org/10.1016/j.semcancer.2017.10.003

Chicago Style (17th ed.) Citation

Dieci, Maria Vittoria, et al. "Update on Tumor-infiltrating Lymphocytes (TILs) in Breast Cancer, Including Recommendations to Assess TILs in Residual Disease After Neoadjuvant Therapy and in Carcinoma in Situ: A Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer." Seminars in Cancer Biology 52 (2018): 16. https://doi.org/10.1016/j.semcancer.2017.10.003.

MLA (9th ed.) Citation

Dieci, Maria Vittoria, et al. "Update on Tumor-infiltrating Lymphocytes (TILs) in Breast Cancer, Including Recommendations to Assess TILs in Residual Disease After Neoadjuvant Therapy and in Carcinoma in Situ: A Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer." Seminars in Cancer Biology, vol. 52, 2018, p. 16, https://doi.org/10.1016/j.semcancer.2017.10.003.